We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Uncertain if Vytorin’s Positive Cardiovascular Results Tell Full Story
FDA Uncertain if Vytorin’s Positive Cardiovascular Results Tell Full Story
As Merck looks to expand the indications of its lipid-reducing drug Vytorin to include cardiovascular outcomes, the FDA is asking whether trial findings describe the full picture well enough to substantiate benefit.